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The Dry Eye Assessment and Management (DREAM) Study was a
multicenter (27 sites), randomized, double-masked clinical trial for
people with moderate to severe dry eye disease (DED).1 Between
October 2014 and July 2016, 535 participants were assigned in a
2:1 ratio to either active omega-3 fatty acid daily supplements (2
g eicosapentaenoic acid and 1 g docosahexaenoic acid) or placebo
(5 g reﬁned olive oil). One-year results showed no difference be-
tween the omega-3 and placebo groups for the primary outcome of
symptoms, as measured by the Ocular Surface Disease Index, or
the traditional signs of DED (conjunctival and corneal staining, tear
ﬁlm break-up time, and Schirmer II test results).1
Additional signs of DED acquired through use of devices were
assessed in the DREAM Study as exploratory outcome measures.
Clinical staff completed a certiﬁcation program including review of
the protocol and instructional slides and a written test for each
device. Measurements were made according to the manufacturer’s
instructions.
Testing was performed on both eyes with the right eye ﬁrst.
Tear osmolarity was measured using the TearLab Osmolarity
System (TearLab, San Diego, CA). The Keratograph 5M (Oculus,
Arlington, WA) was used for noninvasive keratographic tear ﬁlm
break-up time, tear meniscus height, bulbar conjunctival redness,
and meibomian gland imaging. The examiner everted each eyelid
and used the keratograph’s infrared photography system to capture
images of meibomian glands. Examiners graded meibomian gland
dropout on the Pult scale.2 When lid eversion or image quality was
insufﬁcient to judge dropout area, the result was classiﬁed as
missing. Matrix metalloproteinase (MMP) 9 testing was
performed with the InﬂammaDry system (RPS Diagnostics,
Sarasota, FL). Keratography and tear osmolarity testing was
conducted only at centers equipped with the devices. Testing was
at baseline, 6 months, and 12 months, except for MMP 9 testing
(carried out at screening and 3 months).
Differences between treatment groups were estimated with
regression models using a generalized estimating equations
approach to account for intereye correlation. Subgroups were
deﬁned based on the baseline values of the measures for signs,
using category bounds to form tertiles or, for tear osmolarity, a
previously deﬁned threshold for abnormal (308 mOsm/l). Vari-
ation in treatment effects across subgroups was assessed with tests
of interaction.
The DREAM Study protocol was approved by each center’s
institutional review board, complied with the Health Insurance
Portability and Accountability Act, and adhered to the tenets of the
Declaration of Helsinki. Patients provided written informed con-
sent. The trial was registered on ClinicalTrials.gov (identiﬁer,
NCT02128763).
The baseline mean  standard deviation value of tear osmo-
larity in the active group (303.917.2 mOsm/l) was higher than in
the placebo group (300.614.5 mOsm/l; P ¼ 0.02; Table S1,
available at www.aaojournal.org). The mean change was a
decrease of 0.7 mOsm/l in the active group and an increase of
3.6 mOsm/l in the placebo group, yielding a difference of 4.3
mOsm/l (P ¼ 0.02; Table S2, available at www.aaojournal.org;
Fig 1A).
The baseline keratography measurements were similar between
treatment groups (Table S1). The mean noninvasive keratographic
tear ﬁlm break-up time decreased by 0.5 second in each group
(P ¼ 0.97; Table S2; Fig 1B). The change in mean tear meniscus
height was near 0 in the active (0.00 mm) and placebo (e0.01 mm)
groups (P ¼ 0.71; Table S2; Fig 1C). The mean change in bulbar
conjunctival redness score was near 0 in the active (0.00) and
placebo (e0.01) groups (P ¼ 0.81; Table S2; Fig 1D). The
percentage of eyes with Pult scale scores indicating
improvement, stability, or worsening by 1 or more categories
was similar for the upper lid (P ¼ 0.34) and lower lid
(P ¼ 0.21; Table S2).
At baseline, the MMP 9 test showed positive results for similar
proportions of eyes in the active (33%) and placebo (30%) groups.
Between baseline and 3 months, 10% of eyes in the active group
and 13% of eyes in the placebo group converted negative to pos-
itive results, and 13% of each group converted from positive to
negative results (P ¼ 0.69; Table S2).
Results of analyses of the mean difference between active and
placebo groups within subgroups are displayed in Table S3
(available at www.aaojournal.org). None of the tests of
interaction showed statistically signiﬁcant results (all P  0.39).
In this randomized, double-masked clinical trial, there were no
signiﬁcant differences between daily supplementation with omega-
3 versus reﬁned olive oil supplementation in noninvasive kerato-
graphic tear ﬁlm break-up time, tear meniscus height, bulbar
conjunctival redness, upper and lower lid meibography, and MMP
9 positivity (all P> 0.21). Only the mean change in tear osmolarity
yielded a statistically signiﬁcant difference, with slight improve-
ment in the active treatment group (e0.7 mOsm/l) when compared
with the worsening in the placebo treatment group (þ3.6 mOsm/l).
The mean changes over time within each treatment group were
small for keratography measures, and the net change in classiﬁ-
cation of meibomian gland dropout and MMP 9 positivity was
small. When subgroups were examined, there was no evidence of a
greater beneﬁt of omega-3 supplementation among eyes with more
abnormal values at baseline.
Although a small improvement was observed in the mean
change in tear osmolarity for the active group and a worsening in
the placebo group, there was no difference between the active and
placebo groups at 12 months (303.118.4 mOsm/l vs. 303.3 17.5
mOsm/l; P ¼ 0.90). These ﬁndings are difﬁcult to interpret given
the high variability among readings from the TearLab system and
lack of correlation changes in tear osmolarity with changes in
symptoms or corneal ﬂuorescein staining.3,4
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